Explore
Upload

DocSlides is a free service to upload presentations and documents.

Upload Now

Search Results for 'Trastuzumab Biosimilar'

Trastuzumab Biosimilar published presentations and documents on DocSlides.

PSHP President’s Update

PSHP President’s Update

  • olivia-moreira
  • 0 Slides

PSHP Annual Assembly. October 28, 2015. Matt Scol...

National Pharmacy Practice

National Pharmacy Practice

  • debby-jeon
  • 0 Slides

Gene Dorr . Area Vice President, PBM Consulting. ...

Biosimilar Biological Products

Biosimilar Biological Products

  • luanne-stotts
  • 0 Slides

2016 . Clinical Investigator . Training Course. S...

Comparison of US/EU Biosimilar

Comparison of US/EU Biosimilar

  • myesha-ticknor
  • 0 Slides

Guidelines. Kamali Chance, MPH, PhD, RAC. Senior...

U.S. Biosimilars: An Introduction

U.S. Biosimilars: An Introduction

  • calandra-battersby
  • 0 Slides

Disclaimers. :. By 2016, 7 of the top 10 pharmace...

Comparison of US/EU Biosimilar

Comparison of US/EU Biosimilar

  • aaron
  • 0 Slides

Guidelines. Kamali Chance, MPH, PhD, RAC. Senior...

Phil Johnson MS RPh Safe School Meds, Principle Partner

Phil Johnson MS RPh Safe School Meds, Principle Partner

  • yoshiko-marsland
  • 0 Slides

Moffitt Cancer Center, Director of Pharmacy (Reti...

Latin American Physician Perspectives on Biosimilars

Latin American Physician Perspectives on Biosimilars

  • celsa-spraggs
  • 0 Slides

Presented at the . Latin American Biologics/Biosi...

Biosimilars in emerging markets- regulatory and Commercial considerations

Biosimilars in emerging markets- regulatory and Commercial considerations

  • jane-oiler
  • 0 Slides

OMIC Group. Biosimilars 2104. Hyderabad. India. 2...

Challenges in demonstrating biosimilarity and interchangeability of biosimilar products

Challenges in demonstrating biosimilarity and interchangeability of biosimilar products

  • calandra-battersby
  • 0 Slides

OMIC Group Biosimilars 2014. Hyderabad India. 27-...

The generic and biosimilar

The generic and biosimilar

  • alida-meadow
  • 0 Slides

perspective. Warwick Smith. Director General BGMA...

Systemic Therapy for Breast Cancer

Systemic Therapy for Breast Cancer

  • natalia-silvester
  • 0 Slides

Adjuvant or Neoadjuvant. Agustin A Garcia, MD, MM...

Updates in the Treatment of Breast cancer

Updates in the Treatment of Breast cancer

  • alexa-scheidler
  • 0 Slides

Mohammad . Jahanzeb. , MD, FACP. Professor of Cli...

PSHP President’s Update

PSHP President’s Update

  • myesha-ticknor
  • 0 Slides

PSHP Annual Assembly. October 28, 2015. Matt Scol...

Neoadjuvant Target Therapy in Her-2 Positive Breast Cancer

Neoadjuvant Target Therapy in Her-2 Positive Breast Cancer

  • faustina-dinatale
  • 0 Slides

Dr. . Khaled Abulkhair, PhD. Medical Oncology SCE...

Management of HER2 Over-Expressed Breast Cancer in the Adjuvant, Neoadjuvant, and Metastatic settings

Management of HER2 Over-Expressed Breast Cancer in the Adjuvant, Neoadjuvant, and Metastatic settings

  • marina-yarberry
  • 68 Slides

Management of HER2 Over-Expressed Breast Cancer i...

Eribulin Mesylate + Trastuzumab

Eribulin Mesylate + Trastuzumab

  • easyho
  • 10 Slides

as First-Line Therapy for Locally Recurrent or . M...

Module 9: HER2-Positive and

Module 9: HER2-Positive and

  • norah
  • 38 Slides

Triple-Negative Breast Cancer. Jamie Carroll, APRN...

22 MayEMACHMPBWP2477132012Committee for Medicinal Products for Hum

22 MayEMACHMPBWP2477132012Committee for Medicinal Products for Hum

  • carla
  • 9 Slides

Adoption by CHMP for release for consultation24 Ma...

Part B Medical Drugs Requiring Step

Part B Medical Drugs Requiring Step

  • udeline
  • 1 Slides

-TherapyDrug subject to Step TherapyTry these Opti...

Part B Medical Drugs Requiring StepTherapy

Part B Medical Drugs Requiring StepTherapy

  • natalie
  • 1 Slides

Drug subject to Step Therapy BRAND NAME GENERIC NA...

INSIGHTS INTO THE MARKET

INSIGHTS INTO THE MARKET

  • summer
  • 20 Slides

FOR INFLIXIMABTable of ContentsThe Evolving Landsc...

Nonproprietary Naming of Biological ProductsGuidance for IndustryUS De

Nonproprietary Naming of Biological ProductsGuidance for IndustryUS De

  • anastasia
  • 15 Slides

x0000x0000 x/Attxachexd /xBottxom x/BBoxx 3x014x33...

Dawid Sigorski, Ph.D .

Dawid Sigorski, Ph.D .

  • morgan
  • 65 Slides

Department. of . oncology. . UWM. Epidemiology. ...

Improving Your Formulary and Denials Management

Improving Your Formulary and Denials Management

  • trinity
  • 35 Slides

Zinkeng Asonganyi, PharmD. Director of Pharmacy Se...

Budget impact and cost-effectiveness of oncology

Budget impact and cost-effectiveness of oncology

  • roxanne
  • 14 Slides

biosimilars. Prof. dr. Steven Simoens. Health econ...

Cost Impact Of Biosimiliars in Oncology

Cost Impact Of Biosimiliars in Oncology

  • williams
  • 29 Slides

Mansoor A Khan, BS, MS, BCOP. Senior Clinical Phar...

DRUG NAMES AND MEDICATION ERRORS

DRUG NAMES AND MEDICATION ERRORS

  • freya
  • 13 Slides

1. DRUG NAMES. Chemical name. Development name use...

HER2 positive breast carcinoma in the pre and post adjuvant anti-HER-2 therapy era: a single academ

HER2 positive breast carcinoma in the pre and post adjuvant anti-HER-2 therapy era: a single academ

  • carny
  • 14 Slides

Heather M. Gage, MD, Avanti . Rangnekar. , Robert ...

Breast Cancer in Older Patients

Breast Cancer in Older Patients

  • ButterflyKisses
  • 51 Slides

Key Issues. Etienne GC . Brain. , MD . PhD. Instit...

Medicare Part B Step Therapy Programs

Medicare Part B Step Therapy Programs

  • elina
  • 10 Slides

Page 1 of 10 UnitedHealthcare Medicare Advantag...

CoclusteringofErbB1andErbB2RevealedbyFRETSensitizedAcceptorBleachingg

CoclusteringofErbB1andErbB2RevealedbyFRETSensitizedAcceptorBleachingg

  • cora
  • 10 Slides

SubmittedDecember10,2009,andacceptedforpublication...

NEUPOGEN filgrastim

NEUPOGEN filgrastim

  • gelbero
  • 5 Slides

GRANIX (tbo - filgrastim), NIVESTYM (filgrastim -...

Prescription Drug Resource Center

Prescription Drug Resource Center

  • roberts
  • 4 Slides

Generic Drug Substitution Laws May 3 , 2019 Compi...

Antibody–Drug Conjugates in Development for Non-

Antibody–Drug Conjugates in Development for Non-

  • elizabeth
  • 49 Slides

s. mall Cell . Lung Cancer. , Gastric Cancer, and ...

Antibody–Drug Conjugates

Antibody–Drug Conjugates

  • wang
  • 55 Slides

in Development for . Breast Cancer. Sara A. Hurvit...

Antibody–Drug Conjugates: Practical Considerations and Applications in Clinical Use

Antibody–Drug Conjugates: Practical Considerations and Applications in Clinical Use

  • gelbero
  • 35 Slides

Sara A. Hurvitz, MD, FACP. Professor of Medicine. ...

1 Immunogenicity The key safety issue for biosimilars

1 Immunogenicity The key safety issue for biosimilars

  • gelbero
  • 29 Slides

Prof. Ibrahim A. . Alsarra. Professor . of . Phar...

Challenges in Assessing Therapeutic Equivalence of

Challenges in Assessing Therapeutic Equivalence of

  • thomas
  • 27 Slides

Nanosimilars. Beat . Flühmann. Global Lead NBCD ....

Risk of Heart Failure in Breast Cancer Patients After

Risk of Heart Failure in Breast Cancer Patients After

  • sophia2
  • 27 Slides

Anthracycline. and . Trastuzumab. Treatment: A R...

Copyright © 2024 DocSlides. All Rights Reserved